US Patent Issued to JIANGSU KANION PHARMACEUTICAL on Aug. 4 for "Anti-human CD73 monoclonal antibody without hook effect" (Chinese Inventors)

ALEXANDRIA, Va., Aug. 5 -- United States Patent no. 12,698,336, issued on Aug. 4, was assigned to JIANGSU KANION PHARMACEUTICAL Co. LTD. (Liangyungang, China).

"Anti-human CD73 monoclonal antibody without hook effect" was invented by Gaoyong Liao (Nanjing, China), Haijian Ding (Nanjing, China) and Yi Zhang (Nanjing, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides a novel anti-CD73 monoclonal antibody. The antibody has high affinity for human CD73 protein. Both biochemical-level and cell-level experiments show that the antibody is highly effective in inhibiting the enzyme activity of CD73. The in-vivo experiment indicates that the antibody has a significant inhibition effec...